BeStock  
Stocks › Biotechnology › DSGN

Design Therapeutics DSGN

US equityMarket cap rank #3510Biotechnology
$9.02 −$0.30 (-3.22%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.02 0.00%
Open$9.33
Prev close$9.32
Day range$8.96 – $9.57
Volume281.9K
Market cap$577.61M
P/E (TTM)–
Dividend yield–

DSGN Stock News

Headlines matching Design Therapeutics or the DSGN ticker, most recent first.

  • Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22Market news · 4 Aug 2026 · Direct mention
  • Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21Market news · 15 Jun 2026 · Direct mention
  • Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21 PositiveMarket news · 4 May 2026 · Direct mention
  • Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20Market news · 27 May 2026 · Direct mention
  • RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 PositiveMarket news · 20 May 2026 · Direct mention
  • Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 PositiveMarket news · 19 May 2026 · Direct mention
  • Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 PositiveMarket news · 29 Apr 2026 · Direct mention
  • RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $14 PositiveMarket news · 29 Apr 2026 · Direct mention
  • Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $15Market news · 29 Apr 2026 · Direct mention
  • Jefferies Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15Market news · 16 Mar 2026 · Direct mention
  • Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $18Market news · 10 Mar 2026 · Direct mention
  • RBC Capital Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $14Market news · 10 Mar 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)TipRanks · 10 Mar 2026 · Direct mention
  • Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20Market news · 5 Nov 2026 · Direct mention
  • RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Cuts Target Price to $19 NegativeMarket news · 5 Nov 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on DSGN.

Sign in to join the discussion.

Scroll to Top